Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OnabotulinumtoxinA (BOTOX) Treatment for Urinary Incontinence in Patients With Overactive Bladder

Trial Profile

OnabotulinumtoxinA (BOTOX) Treatment for Urinary Incontinence in Patients With Overactive Bladder

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms COMFORT
  • Sponsors Allergan
  • Most Recent Events

    • 31 Aug 2018 Results assessing the early and consistent improvements in urinary symptoms and quality of life in idiopathic overactive bladder patients following repeat treatment with onabotulinumtoxinA, presented at the 48th Annual Meeting of the International Continence Society.
    • 21 May 2018 Primary endpoint (Change from Baseline in Number of Episodes of Urinary Incontinence) has been met, presented at the 113th Annual Meeting of the American Urological Association.
    • 21 May 2018 Primary endpoint (Percentage of Participants who Achieve a 100% Reduction in Urinary Incontinence Episodes) has been met, presented at the 113th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top